A comprehensive examination of Low Dose Naltrexone – a little-known drug with big potential
New drug [LDN] raises hopes of reversing memory loss in old age the Guardian
A drug that is simultaneously affordable, devoid of severe side effects, and applicable to a wide range of diseases is not often found in the modern pharmaceutical landscape. But as medical professionals and researchers alike continue to discover, Low Dose Naltrexone (LDN) boasts this remarkable combination.
Expanding on the information presented in The LDN Book, Volume 1 – which showcased LDN’s efficacy in treating conditions such as lupus, thyroiditis, autism spectrum disorder, and chronic fatigue – Volume 2 highlights the latest clinical trials, case studies and research on LDN. More than a dozen medical professionals explain how they are using LDN to help patients suffering from:
- Chronic pain
- Parkinson’s disease
- Dermatologic conditions
- Traumatic brain injury
- Lyme disease and more.
Volume 1 and Volume 2 have been edited by Linda Elsegood, founder of the UK-based LDN Research Trust. Through the Trust and her work on the LDN books, Linda has connected thousands of patients, doctors and pharmacists around the world with information, articles and patient stories about LDN. The LDN Book, Volume 2 is a fantastic resource for practitioners, pharmacists and patients and a renewed call for further research on the healing potential of this beneficial drug.
